Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Capital Expenditures (2020 - 2025)

Bolt Biotherapeutics' Capital Expenditures history spans 6 years, with the latest figure at $72000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures rose 1700.0% year-over-year to $72000.0; the TTM value through Sep 2025 reached $72000.0, up 53.19%, while the annual FY2023 figure was $206000.0, 89.45% down from the prior year.
  • Capital Expenditures for Q3 2025 was $72000.0 at Bolt Biotherapeutics, up from -$41000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.7 million in Q4 2021 and bottomed at -$507000.0 in Q2 2022.
  • The 5-year median for Capital Expenditures is $65000.0 (2021), against an average of $285562.5.
  • The largest annual shift saw Capital Expenditures plummeted 783.33% in 2024 before it skyrocketed 1700.0% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $1.7 million in 2021, then tumbled by 89.47% to $184000.0 in 2022, then tumbled by 96.74% to $6000.0 in 2023, then plummeted by 783.33% to -$41000.0 in 2024, then soared by 275.61% to $72000.0 in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Capital Expenditures are $72000.0 (Q3 2025), -$41000.0 (Q4 2024), and $4000.0 (Q3 2024).